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Background-—Magnesium is associated with lower risk of sudden cardiac death, possibly through antiarrhythmic mechanisms.
Magnesium inﬂuences endothelial function, inﬂammation, blood pressure, and diabetes, but a direct relation with coronary heart
disease (CHD) risk has not been established.
Methods and Results-—We prospectively examined the association between dietary and plasma magnesium and risk of CHD
among women in the Nurses’ Health Study. The association for magnesium intake was examined among 86 323 women free of
disease in 1980. Information on magnesium intake and lifestyle factors was ascertained every 2 to 4 years through questionnaires.
Through 2008, 3614 cases of CHD (2511 nonfatal/1103 fatal) were documented. For plasma magnesium, we conducted a nested
case–control analysis, with 458 cases of incident CHD (400 nonfatal/58 fatal) matched to controls (1:1) on age, smoking, fasting
status, and date of blood sampling. Higher magnesium intake was not associated with lower risk of total CHD (P-linear trend=0.12)
or nonfatal CHD (P-linear trend=0.88) in multivariable models. However, magnesium intake was inversely associated with risk of
fatal CHD. The RR comparing quintile 5 to quintile 1 of magnesium intake was 0.61 (95% CI, 0.45 to 0.84; P-linear trend=0.003).
The association between magnesium intake and risk of fatal CHD appeared to be mediated partially by hypertension. Plasma
magnesium levels above 2.0 mg/dL were associated with lower risk of CHD, although not independent of other cardiovascular
biomarkers (RR, 0.67; 95% CI, 0.44 to 1.04).
Conclusions-—Dietary and plasma magnesium were not associated with total CHD incidence in this population of women. Dietary
magnesium intake was inversely associated with fatal CHD, which may be mediated in part by hypertension. (J Am Heart Assoc.
2013;2:e000114 doi: 10.1161/JAHA.113.000114)
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M
agnesium is a principal intracellular cation in human
cells and is an activator of >300 enzymes, most
notably, sodium potassium ATPase.
1 Thus, magnesium plays a
vital role in numerous diverse cellular processes, including
cardiovascular pathways. Previously, we reported a strong
inverse association between dietary and plasma magnesium
and risk of sudden cardiac death (SCD) in the Nurses’ Health
Study (NHS).
2 We hypothesized that this association might be
explained, in part, by the antiarrhythmic properties of
magnesium.
3 However, magnesium also has beneﬁcial effects
on traditional coronary heart disease (CHD) risk factors such
as blood pressure,
4 diabetes,
5 and lipids,
6 which might also
explain part of the association with SCD. Further, magnesium
may also lower risk of CHD directly through these athero-
sclerotic risk factors; however, a direct relationship between
serum and/or dietary magnesium and CHD risk has not been
clearly established. Serum and dietary magnesium have been
inversely associated with CHD risk in some
7–9 but not all
10,11
epidemiological studies, and few studies have examined the
association for serum and dietary magnesium within the same
population.
To address these uncertainties, we examined the associ-
ation between dietary and plasma magnesium and risk of CHD
among middle-aged and older women in the NHS. In addition,
to evaluate whether the association between magnesium and
CHD could be explained fully through traditional cardio-
vascular pathways, we quantiﬁed the degree to which its
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tes, and hypercholesterolemia.
Methods
Study Population
The NHS began in 1976 and consists of 121 700 female
nurses 30 to 55 years old at baseline.
12 Every 2 years,
information on lifestyle habits, cardiovascular disease (CVD)
risk factors, and newly diagnosed diseases is ascertained
through self-administered questionnaires. Between 1989 and
1990, 32 826 women in this cohort provided a blood sample.
The study was approved by the institutional review board at
Brigham and Women’s Hospital. Return of the baseline
questionnaire implied informed consent.
End-Point Ascertainment and Deﬁnitions
Incident CHD was deﬁned as nonfatal myocardial infarction
(MI) or fatal CHD. MIs were deﬁned by WHO criteria.
13 Fatal
CHD was deﬁned as a fatal MI, according to autopsy or
hospital records, or if CHD was listed as the cause of death
and other evidence of CHD was present. We also included
fatal events presumed to be CHD based on a death certiﬁcate
alone. All CHD cases were conﬁrmed by study physicians
blinded to participants’ risk factor status.
Assessment of Magnesium Intake
Information on usual diet was ascertained via food frequency
questionnaires (FFQs) in 1980, 1984, and every 4 years from
1986 to 2006. For each food item, each participant was asked
how often, on average, she had consumed a speciﬁed portion
size over the past year. We calculated the average intake of all
nutrients by multiplying the frequency of consumption of each
food by its nutrient content in the Harvard University Food
Composition Database and summing across all foods. Total
nutrient intake also included supplemental sources. For
magnesium, supplements accounted for an average of
14 mg/day. The Pearson correlation coefﬁcient between
magnesium intake estimated from the FFQ and the average of
two 1-week dietary records was 0.67.
14 All nutrients were
adjusted for total energy intake using the residual method.
15
Measurement of Biochemical Variables
Procedures for blood collection and storage have been
described previously.
16 Plasma magnesium was measured by
a colorimetric assay (Roche Diagnostics, Indianapolis, IN).
The coefﬁcient of variation (CV) was 4%. We measured total
cholesterol, high-density lipoprotein cholesterol (HDL-C) and
low-density lipoprotein cholesterol (LDL-C), high-sensitivity
C-reactive protein (hsCRP), adiponectin, and hemoglobin A1c
(HbA1c), as described previously.
17 The CVs were <15% for
adiponectin and <5% for other biomarkers. We used plasma
creatinine (CV=12.8%), measured by a modiﬁed Jaffe method,
to estimate the glomerular ﬁltration rate (eGFR), based on
the Modiﬁcation of Diet in Renal Disease Study Group
equation.
Statistical Analysis
Dietary magnesium
The association between magnesium intake and CHD was
analyzed in a prospective cohort design among the 86 323
women free of CHD and cancer and who provided valid dietary
data (ie, <10 food items blank and total energy intake
between 600 and 3500 kcal/day).
We calculated the cumulative average of total energy and
magnesium and other nutrients to best represent long-term
diet and to reduce measurement error.
18 For CHD incidence
during 1984–1986, we used the average of magnesium intake
in 1980 and 1984, for CHD incidence during 1986–1990, we
used the average magnesium intake in 1980, 1984, and 1986,
and so forth.
Dietary changes can occur after the development of
intermediate end points in the causal pathway between
magnesium intake and CHD, such as hypercholesterolemia,
hypertension, and diabetes, which may then confound the
association. Therefore, we assessed whether a diagnosis of
these intermediate events was associated with a subsequent
change in magnesium intake.
19 If we detected a signiﬁcant
change after the diagnosis of the intermediate event, we
stopped updating magnesium intake to avoid time-dependent
confounding by the intermediate event. If magnesium intake
was not signiﬁcantly different, we continued to update
magnesium intake to avoid misclassiﬁcation of the partici-
pants’ long-term magnesium intake. This approach represents
our best efforts to account for confounding by intermediate
events and to minimize misclassiﬁcation of an individual’s
long-term diet.
Women contributed person-time from date of return of the
1980 questionnaire until the date of CHD diagnosis, date of
death, or June 1, 2008, whichever came ﬁrst. We calculated
the hazard ratio (95% CI) of CHD by quintiles of magnesium
intake using multivariable Cox proportional hazard models as
an estimate of the relative risk (RR), adjusting for potential
confounders. Magnesium intake and other covariates, except
for parental history of MI, were updated during follow-up and
included as time-varying covariates in the models. In separate
models, we adjusted for history of diabetes, hypertension, and
hypercholesterolemia at baseline and development of these
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covariates). Hypertension was deﬁned as self-reported
physician diagnosis of disease and/or reported use of anti-
hypertensive medication. To test for a linear trend, we
assigned each quintile the median value and modeled this
variable as a continuous variable. We examined potential
deviation from linearity with a likelihood ratio test, comparing
a model with the linear term with a model including the linear
term plus restricted cubic spline transformations.
20 The
assumption of proportional hazards was met.
To quantify the potential mediating effect of intermediate
diseases (hypertension, diabetes, and high cholesterol), we
calculated the mediation proportion, which is the proportion
of the protective effect of magnesium intake on CHD risk that
can be explained by associations with hypertension, diabetes,
and hypercholesterolemia. For these models, information on
these covariates was updated during follow-up and included
as time-varying covariates in the models. We then estimated
the change in beta-coefﬁcient for a 100-mg increment of
magnesium intake, comparing models with and without
potential intermediates.
Plasma magnesium
We used a prospective nested case–control design to
estimate the association between plasma magnesium and
risk of CHD. Among the women who provided a blood sample
and were free of CVD, 458 cases of CHD (400 nonfatal/58
fatal) occurred after return of the blood sample and before
June 1, 2006. We randomly selected 1 control for each case
among women free of CVD at the time of case diagnosis,
matched on age (1 year), smoking status (never/past/
current), fasting status (yes/no), and month of blood draw.
Magnesium and other assays were performed on the case–
control pairs in the same analytical run, with laboratory
personnel blinded to case status.
Age-adjusted Spearman correlations quantiﬁed the asso-
ciation between plasma and dietary magnesium. Plasma
magnesium was categorized into quartiles based on the
distribution among the control participants. We used condi-
tional logistic regression to estimate the relative risk (95% CI)
of plasma magnesium in relation to CHD incidence. With a
risk-set sampled case–control design, the odds ratio
estimated from the logistic regression model validly estimates
the incidence ratio
21 and thus the relative risk. Models were
further adjusted for potential confounders ascertained in
1990, the year of blood collection. Tests for linear trend,
deviation from linearity, and mediation proportion estimates
per 1 standard deviation increment of plasma magnesium
(0.2 mg/dL) were performed as described above. All statis-
tical analysis was performed using SAS software (version 9).
A P value <0.05 was considered statistically signiﬁcant.
Results
Dietary Magnesium Analysis
Women with higher magnesium intake tended to be older;
more likely to smoke, take multivitamins, and be more
physically active; have higher intake of potassium, vitamin D,
polyunsaturated:saturated fat, and cereal ﬁber; and have
lower intake of trans fats (Table 1). Over a median follow-up
of 28 years, we documented 3614 cases of CHD (2511
nonfatal/1103 fatal events). Higher magnesium intake was
associated with lower risk of total CHD in models adjusting for
potential confounders (Table 2, model 1), but this association
was attenuated and no longer signiﬁcant after further
adjustment for hypertension, diabetes, and hypercholesterol-
emia at baseline (Table 2, model 2). This attenuation was
driven primarily by hypertension. Finally, results were consis-
tent in age-stratiﬁed analysis. The RR of total CHD, comparing
quintile 5 with quintile 1 of dietary magnesium, was 0.86 (95%
CI, 0.61 to 1.22) among women <60 years and 0.90 (95% CI,
0.74 to 1.11) for women ≥60 years.
Magnesium intake was not associated with risk of nonfatal
CHD but was signiﬁcantly inversely associated with risk of
fatal CHD (Table 2). The multivariable RR of fatal CHD was
0.61 (95% CI, 0.45 to 0.84) comparing the highest quintile
with the lowest quintile of magnesium intake (model 2).
This inverse association remained signiﬁcant after exclud-
ing sudden and/or arrhythmic cardiac deaths (n=187;
multivariable RR for top quintile, 0.68; 95% CI, 0.48 to 0.96)
and when we excluded fatal events based on death certiﬁ-
cates alone (n=288; multivariable RR, 0.61; 95% CI, 0.42 to
0.87). When we explored the association between magnesium
from food sources only and risk of fatal CHD, results were
similar (RR, 0.65; 95% CI, 0.47 to 0.89). We detected no
deviation from linearity in the relation between dietary
magnesium and risk of total, fatal, and nonfatal CHD. The
RR of fatal CHD per a 100 mg/day increment of dietary
magnesium was 0.70 (95% CI, 0.56 to 0.87) adjusting for
potential confounders (Table 3).
Next, we explored potential mechanistic pathways through
which magnesium intake may lower CHD risk. After adjusting
for diabetes, hypertension, and hypercholesterolemia
throughout follow-up, magnesium intake remained signiﬁ-
cantly associated with risk of fatal CHD (Table 2, model 3). In
mediation analyses, the association between magnesium and
hypertension accounted for 29% (95% CI, 11% to 47%) and
23% (95% CI, 10% to 36%) of the association between
magnesium intake and total and fatal CHD, respectively
(Table 3). Diabetes explained 8% (95% CI, 2% to 14%) of the
association between magnesium intake on risk of total CHD
and was not a mediator for fatal CHD. Self-reported
hypercholesterolemia was not a mediator. Magnesium intake
was not signiﬁcantly associated with risk of nonfatal CHD;
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outcome.
Plasma Magnesium Analysis
The characteristics of the population by quartiles of plasma
magnesium are presented in Table 4. Women with higher
plasma magnesium were less likely to have diabetes and use
hormone therapy and had higher LDL cholesterol, lower
hsCRP, and lower eGFR. Plasma magnesium was not signif-
icantly correlated with dietary magnesium (r=0.02, P=0.50).
We did not observe a linear inverse association between
plasma magnesium and risk of CHD in models adjusting for
potential confounders (P–test for linear trend=0.22; Table 5,
model 2). However, we found a signiﬁcantly lower risk of CHD
in the second quartile of plasma magnesium, with minimal
change with higher concentration (RR for magnesium ≥2.1
versus <2.1 mg/dL, 0.65; 95% CI, 0.44 to 0.96). Results were
not appreciably altered after further adjustment for magne-
sium intake and baseline disease status (Table 5), and the
L-shaped association was conﬁrmed in spline analysis
(Figure). After adjustment for potential intermediary cardio-
vascular biomarkers, the association was attenuated and no
longer signiﬁcant (RR for magnesium ≥2.1 versus <2.1 mg/dL,
0.67; 95% CI, 0.44 to 1.04; Table 5). With only 58 cases of
fatal CHD, our power to draw any conclusions about the
relation between plasma magnesium and fatal CHD separately
was limited.
Discussion
In this prospective cohort of women, higher magnesium
intake was associated with lower risk of fatal CHD, indepen-
dent of known CHD risk factors. Women with the highest
compared with the lowest intake of magnesium had a 39%
lower risk of fatal CHD, and this association was mediated
partially by hypertension. Dietary magnesium was not asso-
ciated with nonfatal CHD after controlling for cardiovascular
risk factors. Plasma magnesium was associated with risk of
CHD in an L-shaped fashion. Higher concentration of plasma
Table 1. Baseline Characteristics* Among Women in the Nurses’ Health Study by Quintile (Q) of Magnesium Intake
Magnesium Intake
Q1 Q2 Q3 Q4 Q5
Range of magnesium, mg/day <246 246 to 276 277 to 305 306 to 342 >342
n 21 867 15 988 14 955 15 279 18 234
Age, y 45 (7)
† 46 (7) 47 (7) 47 (7) 48 (7)
Current smoker, % 27 28 29 30 31
BMI, kg/m
2 24.7 (4.9) 24.4 (4.6) 24.2 (4.3) 24.2 (4.2) 24.2 (4.2)
Physical activity, h/week 3.5 (2.8) 3.7 (2.9) 3.9 (2.9) 4.1 (2.9) 4.4 (2.9)
Current use of hormone therapy, % 8 8888
Multivitamin use, % 29 32 35 36 39
Aspirin use, % 14 14 14 15 15
Nutrients
Potassium, mg/day 2123 (325) 2535 (294) 2769 (327) 3007 (366) 3466 (523)
Vitamin D, IU/day 267 (248) 304 (262) 332 (280) 353 (292) 399 (318)
Trans fat, g/day 4.5 (1.4) 4.2 (1.2) 4.0 (1.2) 3.9 (1.3) 3.4 (1.3)
Polyunsaturated:saturated fat 0.33 (0.12) 0.34 (0.12) 0.34 (0.12) 0.35 (0.13) 0.38 (0.16)
Cereal ﬁber, g/day 2.1 (1.3) 2.4 (1.4) 2.5 (1.5) 2.6 (1.6) 2.8 (1.7)
Alcohol, g/day 5.8 (10.8) 6.2 (10.2) 6.6 (10.2) 6.8 (10.7) 6.9 (10.8)
History of comorbidities, %
Hypertension 17 16 15 15 15
Diabetes 2 2222
High cholesterol 5 5556
BMI indicates body mass index; SD, standard deviation.
*All nutrients except alcohol were energy adjusted.
†Mean (SD).
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HTable 2. Relative Risk (95% CI) of Total, Nonfatal, and Fatal CHD by Quintile (Q) of Magnesium Intake
Magnesium Intake
P–Linear Trend* Q1 Q2 Q3 Q4 Q5
Range of magnesium, mg/day <246 246 to 276 277 to 305 306 to 342 >342
Person-years 469 774 462 968 471 581 472 193 471 093
Total CHD
Cases 698 736 731 752 697
Age-adjusted model 1.0 (ref) 0.91 (0.82 to 1.01) 0.82 (0.74 to 0.91) 0.79 (0.71 to 0.88) 0.70 (0.63 to 0.78) <0.001
Multivariable model 1
† 1.0 (ref) 0.98 (0.87 to 1.10) 0.91 (0.79 to 1.04) 0.90 (0.77 to 1.05) 0.83 (0.69 to 0.98) 0.02
Multivariable model 2
‡ 1.0 (ref) 0.99 (0.87 to 1.11) 0.94 (0.82 to 1.08) 0.95 (0.82 to 1.11) 0.88 (0.74 to 1.04) 0.12
Multivariable model 3
§ 1.0 (ref) 0.99 (0.88 to 1.12) 0.93 (0.81 to 1.06) 0.95 (0.81 to 1.10) 0.88 (0.74 to 1.05) 0.15
Nonfatal CHD
Cases 474 522 511 514 490
Age-adjusted model 1.0 (ref) 0.97 (0.85 to 1.10) 0.87 (0.77 to 0.99) 0.83 (0.73 to 0.94) 0.76 (0.67 to 0.87) <0.001
Multivariable model 1 1.0 (ref) 1.04 (0.90 to 1.20) 0.98 (0.83 to 1.15) 0.99 (0.82 to 1.18) 0.97 (0.78 to 1.20) 0.66
Multivariable model 2 1.0 (ref) 1.05 (0.91 to 1.21) 1.01 (0.85 to 1.19) 1.04 (0.86 to 1.24) 1.03 (0.83 to 1.27) 0.88
Multivariable model 3 1.0 (ref) 1.05 (0.91 to 1.21) 0.99 (0.84 to 1.17) 1.02 (0.85 to 1.23) 1.02 (0.82 to 1.25) 0.97
Fatal CHD
Cases 224 214 220 238 207
Age-adjusted model 1.0 (ref) 0.78 (0.65 to 0.94) 0.72 (0.60 to 0.87) 0.71 (0.59 to 0.86) 0.58 (0.48 to 0.70) <0.001
Multivariable model 1 1.0 (ref) 0.85 (0.69 to 1.06) 0.77 (0.60 to 0.99) 0.74 (0.56 to 0.97) 0.58 (0.42 to 0.79) <0.001
Multivariable model 2 1.0 (ref) 0.86 (0.69 to 1.07) 0.81 (0.63 to 1.03) 0.79 (0.60 to 1.04) 0.61 (0.45 to 0.84) 0.003
Multivariable model 3 1.0 (ref) 0.85 (0.69 to 1.06) 0.80 (0.62 to 1.02) 0.79 (0.60 to 1.04) 0.64 (0.46 to 0.87) 0.006
CI indicates conﬁdence interval; CHD, coronary heart disease; RR, relative risk; BMI, body mass index; MI, myocardial infarction.
*Test for linear trend estimated by assigning the median value of plasma magnesium in each quartile and modeling this as a continuous variable in regression models.
†RR adjusted for age, calendar year, total calories, smoking, BMI, parental history of MI, alcohol intake, physical activity, menopausal therapy, multivitamin use, and intake of omega-3 fats,
polyunsaturated:saturated fat, trans fat, dietary cholesterol, calcium, cereal ﬁber, potassium, and vitamin D.
‡RR adjusted for covariates in model 1 plus history of hypertension, hypercholesterolemia, and diabetes at baseline.
§RR adjusted for covariates in model 1 plus the development of possible intermediate diseases (hypertension, hypercholesterolemia, and diabetes) during follow-up.
Table 3. Mediation Proportion for the Effect of Magnesium Intake on CHD Risk Explained by Hypertension, Diabetes, and High
Cholesterol
RR (95% CI) per 100 mg Mediation Proportion (95% CI)
Total CHD
Base model* 0.83 (0.74 to 0.94)
Base model+hypertension 0.88 (0.78 to 0.99) 29 (11 to 47)
Base model+diabetes 0.85 (0.75 to 0.95) 8 (2 to 14)
Base model+high cholesterol 0.83 (0.74 to 0.93) N/A
†
Fatal CHD
Base model* 0.70 (0.56 to 0.87)
Base model+hypertension 0.76 (0.62 to 0.94) 23 (10 to 36)
Base model+diabetes 0.71 (0.57 to 0.87) 3 (0.9 to 7)
Base model+high cholesterol 0.70 (0.56 to 0.86) N/A
†
CHD indicates coronary heart disease; RR, relative risk; CI, conﬁdence interval; BMI, body mass index; MI, myocardial infarction.
*RR adjusted for age, total calories, smoking, BMI, parental history of MI, alcohol intake, physical activity, menopausal therapy, multivitamin use, and intake of omega-3 fats,
polyunsaturated:saturated fat, trans fat, dietary cholesterol, calcium, cereal ﬁber, potassium and vitamin D.
†Mediation proportion not calculated because the addition of intermediate variables to the base model did not attenuate the RR.
DOI: 10.1161/JAHA.113.000114 Journal of the American Heart Association 5
Magnesium and CHD Chiuve et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
Hmagnesium was associated with lower risk of CHD, although
this association was not independent of CVD biomarkers.
Prior studies of dietary magnesium and risk of CHD have
yielded conﬂicting results. Two prospective studies found an
inverse association between dietary magnesium and risk of
total CHD among men
8,22; however, in other studies, the
associationbetweendietarymagnesiumandCHDriskhasbeen
null.
7,23 In a meta-analysis of 5 studies, magnesium intake was
not associated with total CHD (RR comparing high with low
magnesium intake, 0.86; 95% CI, 0.67 to 1.10).
11 Consistent
with previous studies, we did not ﬁnd a signiﬁcant association
between dietary magnesium and total CHD risk. In this study,
higher dietary magnesium was only associated with lower fatal
CHD, and discrepant results in prior studies on total CHD could
be due in part to varying proportions of fatal versus nonfatal
events in prior studies. The meta-analysis did not report on the
differential relation with fatal and nonfatal events.
For plasma magnesium, we observed an L-shaped associ-
ation with risk of CHD, in which individuals with plasma
magnesium levels above the second quartile were associated
with lower risk of CHD. This nonlinear association of
circulating magnesium is consistent with previous relation-
ships for arrhythmic end points, including SCD and atrial
ﬁbrillation.
2,24–26 Low serum magnesium has also been more
strongly related to fatal compared with nonfatal CHD
9;
however, we were unable to explore the association between
plasma magnesium and fatal CHD separately. In a recent
study, serum magnesium was not predictive of total CVD,
deﬁned as angina pectoris, CHD, stroke, transient ischemic
attack, heart failure, and intermittent claudication.
10 Any true
Table 4. Characteristics in 1990 by Quartile (Q) of Plasma Magnesium in the Total Population
Plasma Magnesium
Q1 Q2 Q3 Q4
Range of magnesium, mg/dL ≤2.0 2.1 to 2.1 2.2 to 2.3 ≥2.4
n 164 125 405 222
Age, y 58 (7)* 59 (6) 59 (7) 60 (6)
Current smoker, % 24 23 27 23
History of comorbidities, %
Hypertension 42 47 34 33
Diabetes 16 10 9 3
Parental history of MI, % 17 13 18 17
BMI, kg/m
2 26.9 (5.4) 26.4 (5.5) 25.7 (4.6) 25.2 (4.3)
Physical activity, h/week 3.4 (3.3) 3.6 (4.0) 3.6 (4.1) 4.1 (4.0)
eGFR, mL/min per 1.73 m
2† 88 (20) 84 (21) 84 (18) 82 (18)
Cardiovascular biomarkers
LDL-cholesterol, mg/dL 129 (38) 137 (40) 141 (36) 147 (40)
HDL-cholesterol, mg/dL 55 (18) 57 (16) 56 (16) 57 (16)
C-reactive protein, mg/dL 0.49 (0.62) 0.39 (0.54) 0.41 (0.76) 0.28 (0.37)
HbA1C, % 5.8 (1.2) 5.7 (1.1) 5.7 (1.0) 5.5 (0.7)
Adiponectin, mg/L 8264 (4117) 8595 (4535) 8631 (3577) 9217 (4088)
Nutrients
‡
Magnesium, mg/day 304 (77) 304 (61) 306 (72) 310 (80)
Potassium, mg/day 2904 (536) 2912 (451) 2889 (475) 2924 (518)
Calcium, mg/day 1033 (484) 1033 (514) 1072 (531) 1050 (574)
Alcohol, g/day 5.3 (8.8) 4.0 (6.9) 5.5 (9.7) 5.2 (9.3)
Current use of thiazide diuretics, % 25 23 14 16
Current use of postmenopausal hormones, % 49 43 32 35
MI indicates myocardial infarction; BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c;
SD, standard deviation.
*Mean (SD).
†Estimated by the Modiﬁcation of Diet in Renal Disease Study Group equation.
‡All nutrients except alcohol were energy adjusted.
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heterogeneous end point.
Magnesium deﬁciency has been associated with acceler-
ated atherosclerotic progression,
27,28 which may lead to more
aggressive CHD that is more likely to be fatal. Magnesium has
also been associated with beneﬁcial effects on blood
pressure,
4 glucose metabolism,
29 and lipids. Thus, a novel
aspect of this study was the exploration of mediators that
might underlie the association between magnesium and risk of
CHD. We found that hypertension, but not diabetes or
hypercholesterolemia, statistically accounted for part of the
association between dietary magnesium and fatal CHD,
explaining ~23% of the association. However, even after
adjusting for these potential mediators, dietary magnesium
remained signiﬁcantly associated with risk of fatal CHD. The
association between plasma magnesium and CHD was
attenuated and not signiﬁcant after adjustment for potential
intermediate cardiovascular biomarkers; however, this analy-
sis included mostly nonfatal events. These results suggest that
magnesium may prevent fatal CHD through mechanisms
beyond known traditional pathways. Magnesium has been also
been associated with beneﬁcial effects on inﬂammation,
30
endothelial dysfunction,
30 thrombosis,
31 and vascular smooth
muscle cell calciﬁcation,
32 and alterations in these individual
risk factors might inﬂuence the propensity for fatal events.
In addition, magnesium has antiarrhythmic effects,
3,33 and
chronic magnesium deﬁciency may be proarrhythmic.
34,35
In epidemiological studies, low serum magnesium has been
associated with higher risk of atrial ﬁbrillation
24,25
and SCD,
2,26 further supporting a direct link between
hypomagnesemia and cardiac arrhythmias. In this study,
the strong inverse association for fatal CHD persisted even
after the exclusion of known SCD events. Because the
circumstances surrounding the death are not always known,
a proportion of the fatal CHD events that did not fulﬁll the
strict deﬁnition for SCD
36 may have been arrhythmic in
origin. However, these unidentiﬁed events are unlikely to
account for the entire association with fatal CHD. Therefore,
antiarrhythmic actions of magnesium are unlikely to account
entirely for the association observed. Nevertheless, the lack
of ECG data limits our ability to explore the mediation effects
of electrocardiographic intervals.
Clinical trial data regarding magnesium supplementation in
the secondary prevention of CHD are sparse. In several large-
scale randomized trials, intravenous magnesium in the setting
of an acute MI did not reduce mortality rates and low-dose
oral magnesium among 468 acute MI survivors did not lower
risk of cardiac events over 1 year.
37 No clinical trials to date
have assessed magnesium supplementation for the primary
prevention of CHD. It is plausible that only individuals with low
baseline intake may beneﬁt from supplementation.
38 Given
that the current average magnesium intake in the United
States is 261 mg in women and 347 mg in men, which is
below the established RDA (420 and 320 mg/day in men and
women >30 years old, respectively),
39 magnesium supple-
mentation or higher magnesium diets might be beneﬁcial for
the primordial prevention of CHD in the US population.
Although plasma magnesium is a poor biomarker of magne-
sium intake, as evident by the lack of correlation with dietary
magnesium, low-magnesium diets may lead to low serum
Table 5. Relative Risk (95% CI) of CHD by Quartile (Q) of Plasma Magnesium
Plasma Magnesium
Q1 Q2 Q3 Q4
P–Linear
Trend*
RR Comparing ≥2.1
With <2.1 mg/dL
Range of magnesium, mg/dL ≤2.0 2.1 to 2.1 2.2 to 2.3 ≥2.4
Cases 98 55 204 101
Controls 66 70 201 121
Model 1
† 1.0 (ref) 0.51 (0.31 to 0.82) 0.65 (0.44 to 0.96) 0.54 (0.35 to 0.82) 0.04 0.59 (0.41 to 0.85)
Model 2
‡ 1.0 (ref) 0.51 (0.30 to 0.85) 0.73 (0.48 to 1.11) 0.61 (0.39 to 0.97) 0.22 0.65 (0.44 to 0.96)
Model 2+magnesium intake 1.0 (ref) 0.50 (0.30 to 0.84) 0.74 (0.49 to 1.12) 0.61 (0.39 to 0.97) 0.23 0.65 (0.44 to 0.96)
Model 2+diabetes, hypertension,
and high cholesterol at baseline
1.0 (ref) 0.47 (0.27 to 0.81) 0.76 (0.48 to 1.20) 0.60 (0.37 to 0.98) 0.30 0.65 (0.42 to 0.99)
Model 2+HDL-C, LDL-C, hsCRP,
adiponectin, and HbA1c
1.0 (ref) 0.50 (0.28 to 0.88) 0.78 (0.49 to 1.25) 0.63 (0.38 to 1.05) 0.37 0.67 (0.44 to 1.04)
CI indicates conﬁdence interval; CHD, coronary heart disease; RR, relative risk; HDL-C, high-density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; hsCRP, high-
sensitivity C-reactive protein; HbA1c, hemoglobin A1c; BMI, body mass index; MI, myocardial infarction; eGFR, estimated glomerular ﬁltration rate.
*Test for linear trend calculated by assigning the median value of magnesium in each quintile and modeling this as a continuous variable in regression models.
†Model 1: RR estimated from logistic regression models, conditioned on matching factors (age, smoking status, month of blood draw, and fasting status).
‡Model 2: RR further adjusted for BMI, exercise, alcohol intake, family history of MI, eGFR, menopausal therapy, multivitamin use, and intake of omega-3 fats, polyunsaturated:saturated
fat, trans fat, dietary cholesterol, cereal ﬁber, calcium, potassium, and vitamin D.
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40 In addition, magnesium supplementation
can signiﬁcantly increase magnesium stores,
41 particularly
among individuals with hypomagnesaemia at baseline.
42
Ultimately, only a long-term clinical trial of magnesium
supplementation in persons with low dietary intakes with
CHD as the end point can determine the true effect of
magnesium supplementation on CHD prevention.
Our study has several important limitations. First, given the
relatively small number of events in the nested case–control
analysis, we had limited power to explore the association
between serum magnesium and fatal CHD. Second, multivi-
tamins and foods that are major sources of magnesium, such
as whole grains, fruits, vegetables, and nuts, contain many
other nutrients that may lower CHD risk. Therefore, although
we controlled for many variables in our dietary models,
residual confounding by nutrients such as calcium or potas-
sium may explain part of the association between magnesium
and risk of CHD. Third, we used self-reported measures of
potential mediators, as we lacked direct measures of blood
pressure, cholesterol, and glucose in most women in the
cohort analysis and therefore may not have captured the full
mediation effects of these traditional risk factors on the
association between dietary magnesium and CHD risk.
Further, we lacked data on other biomarkers of inﬂammation,
endothelial dysfunction, and thrombosis in the majority of
women and ECG data in all women to assess other mediation
pathways. In the analysis of plasma magnesium, we adjusted
for prevalent hypertension, high cholesterol, and diabetes and
directly measured lipids and inﬂammatory biomarkers.
Because these factors were assessed at the same time as
plasma magnesium, we cannot determine whether low plasma
magnesium was a cause or consequence of elevated biomar-
kers. Therefore, these models may overcontrol for biologic
intermediates.
In conclusion, higher magnesium intake was not associ-
ated with overall CHD risk after controlling for CHD risk
factors, but was associated with a lower risk of fatal CHD.
This latter association was only partially explained by
traditional CHD risk factors. In addition, plasma magnesium
levels above the second quartile were associated with lower
risk of CHD, although not independent of other cardiovascular
biomarkers. Future studies exploring the differential associ-
ation between plasma magnesium and fatal and nonfatal CHD
events are needed. The stronger association of magnesium
intake and risk of fatal CHD and the lack of association
between magnesium and non-fatal CHD in the current study,
in combination with our prior ﬁnding on SCD, further supports
the hypothesis that antiarrhythmic and other actions of
magnesium may reduce the risk of fatal CHD.
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